Search Results - "SCHNELLER, F"

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer by Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J. R., Gargano, M., Patchen, M. L., Walsh, R., Beliveau, M., Marier, J. F., Bose, N., Gorden, K., Schneller, F.

“…Summary Introduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor…”
Get full text

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells by HAHNTOW, I. N, SCHNELLER, F, OELSNER, M, WEICK, K, RINGSHAUSEN, I, FEND, F, PESCHEL, C, DECKER, T

“…A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their activity by inhibition of cyclin-dependent kinases (cdk)…”
Get full text

Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells by RINGSHAUSEN, I, DECHOW, T, SCHNELLER, F, WEICK, K, OELSNER, M, PESCHEL, C, DECKER, T

“…In the present work we investigated the role and biological significance of mitogen activated protein kinases (MAPK) in B-cell chronic lymphocytic leukaemia…”
Get full text

Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin d2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27 by DECKER, T, SCHNELLER, F, HIPP, S, MIETHING, C, JAHN, T, DUYSTER, J, PESCHEL, C

“…B-CLL cells are arrested in G0/early G1 phase of the cell cycle and are characterized by a marked hyporesponsiveness towards a variety of polyclonal B cell…”
Get full text

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C by MÜLLER, M. C, GATTERMANN, N, KRAUSE, S. W, NERL, C, SAYER, H. G, OTTMANN, O. G, WALLER, C, AULITZKY, W, LE COUTRE, P, FREUND, M, MERX, K, PASCHKA, P, LAHAYE, T, KÖNIG, H, KREIL, S, BERGER, U, GSCHAIDMEIER, H, HEHLMANN, R, HOCHHAUS, A, DEININGER, M. W. N, BERNDT, A, FRUEHAUF, S, NEUHAUER, A, FISCHER, T, HOSSFELD, D. K, SCHNELLER, F

“…We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to…”
Get full text

Atypical BCR-ABL mRNA transcripts in adult Acute lymphoblastic leukemia by Burmeister, Thomas, Schwartz, Stefan, Taubald, Almut, Jost, Edgar, Lipp, Thomas, Schneller, Folker, Diedrich, Helmut, Thomssen, Henrike, Mey, Ulrich J.M, Eucker, Jan, Rieder, Harald, Gokbuget, Nicola, Hoelzer, Dieter, Thiel, Eckhard

“…From Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany (TB, SS, ET); Friedrich-Alexander-Universität,…”
Get full text

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma by REICHARDT, Peter, OECHSLE, Karin, PINK, Daniel, BOKEMEYER, Carsten, SCHNELLER, F, ISSELS, Rolf, KANZ, Lothar, HARTMANN, Jörg Thomas

“…The number of effective cytotoxic agents for the treatment of patients with metastatic soft tissue sarcoma (STS) is limited, especially when patients have…”
Get full text

9079 Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase 2 study by Schuette, W, Groeschel, A, Sebastian, M, Andreas, S, Mueller, T, Schneller, F, Guetz, S, Leschinger, M, Buettner, H, Reck, M

Get full text

P27.29.A USE OF FOCAL- COMPARED TO WHOLE BRAIN-RADIOTHERAPY IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN PATIENTS WITH PRIMARY CNS LYMPHOMA - RESULTS OF A LARGE MULTI-CENTRIC ANALYSIS FROM THE NEURO-RADIO-ONCOLOGY WORKING GROUP OF THE GERMAN ASSOCIATION OF RADIATION ONCOLOGY (DEGRO AG NRO) by Heider, S, Rühle, A, Allwohn, L, Ehret, F, Kaul, D, Oertel, M, Pepper, N, Bodensohn, R, Ruder, A M, Merten, R, Combs, S, Bernhardt, D, Schneller, F, Hartong, N, Grosu, A L, Nicolay, N H, Seidel, C

“…Abstract BACKGROUND Primary CNS lymphoma (PCNSL) is a rare but deadly disease. Treatment primarily comprises high-dose chemotherapy involving methotrexate…”
Get full text

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study by von Bubnoff, Nikolas, Schneller, Folker, Peschel, Christian, Duyster, Justus

“…BCR-ABL, a constitutively activated tyrosine kinase, is the oncogene that causes Philadelphia-chromosome-positive (Ph+) leukaemia. STI571, a competitive…”
Get full text

Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors by Schumann, Christian, Sebastian, Martin, Sadjadian, Parvis, Märten, Angela, Abdollahi, A., Aries, S.P., Arntzen, C., Atmaca, A., Basara, N., Borchard, B., Bos, M., Brugger, W., Budweiser, S., Corduan, K., Cortes‐Incio, D., Dallmeier, B., Denzlinger, C., Dittrich, I., Engel‐Riedel, W., Faehling, M., Fertl, A., Fischer, J.R., Fleckenstein, D., Folprecht, G., Forstbauer, A., France, Y., Frickhofen, N., Gardizi, M., Gauler, T., Gessner, C., Gökkurt, E., Görner, M., Grah, C., Greeve, J., Greiner, J., Grohé, C., Grüning, W., Guggenberger, D., Heinrich, B., Hense, G., Hoiczyk, M., Huber, R.M., Illerhaus, G., Jacobs, G., Jung, P., Kern, J., Kersten, J., Kiehl, M., Kisro, J., Knipp, H., Ko, Y.D., Koch, J.U., Koehne, C.H., Kollmeier, J., Kommer, A., Körber, W., Krause, G., Krügel, R., Leistner, R., Liebers, U., Lommatzsch, M., Maintz, C., Mohr, M., Neumeister, W., Overbeck, T., Panse, J., Pelzer, T., Peters, K., Planker, M., Reissig, A., Ritter, M., Sadjadian, P., Sandritter, B., Schatz, M., Scheffler, M., Schmid‐Bindert, G., Schneider, C.P., Schneider‐Kappus, W., Schreiber, J., Schütte, W., Schütz, S., Sebastian, M., Serke, M., Staiger, H., Stehle, I., Stengele, K., Stöhlmacher‐Williams, J., Strapatsas, T., Sulzbach, B., Tessmer, A., Thomas, M., Ukena, D., Wagner, B., Wagner‐Hug, D., Witt, C., Wohlleber, M., Wolf, J., Wricke, K., Zaba, O., Zander, I.

“…Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non‐small cell lung cancer (NSCLC)…”
Get full text

The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation by Froelich, J J, Schneller, F R, Zahn, R K

“…DNA strand breaks are believed to induce carcinogenesis. This study was conducted to analyze induction and repair of irradiation- and chemotherapy-related…”
Get more information

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia : results of a phase-II trial by SCHNELLER, F, SCHULER, M, SCHUMACHER, K, THALER, J, PESCHEL, C, HUBER, C, AULITZKY, W

“…Sixteen patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in myeloid blast crisis were treated with cytarabine (AraC) 600 mg/m2…”
Get full text

Safety of Imprime PGG, A Novel Innate Immune Modulator, in Adults with Stage IV Non-Small Cell Lung Cancer (NSCLC) by Thomas, M., Schneller, F., Sadjadian, P., Hao, Z., Mattson, P., Lowe, J., Huhn, R., Braun, A., Taitt, C.

Get full text

Bioavailability of calcium in breads fortified with different calcium sources by Ranhotra, G.S, Gelroth, J.A, Leinen, S.D, Schneller, F.E

“…This study used young rats as the test model to examine the relative bioavailability (RB) of calcium (Ca) in breads fortified with five different Ca sources…”
Get full text

Efficacy and Safety of Imprime Pgg, a Novel Innate Immune Modulator, in Combination with Bevacizumab (BEV), Carboplatin and Paclitaxel for the 1St-Line Treatment of Stage Iv Nsclc by Braun, A., Engel-Riedel, W., Schneller, F., Wolf, M., Schuette, W., Lowe, J., Mattson, P., Gargano, M., Patchen, M., Huhn, R.

Get full text

Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer by Schuler, M, Peschel, C, Schneller, F, Fichtner, J, Färber, L, Huber, C, Aulitzky, W E

“…Interleukin-6 (IL-6) is a cytokine with pleiotropic biologic activities on B cells, T cells, and hematopoietic progenitors. The present study was undertaken to…”
Get more information

Biotherapy of chronic myelogenous leukemia by AULITZKY, W. E, PESCHEL, C, SCHNELLER, F, HUBER, C

“…The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential…”
Get full text

LBA32IMPRIME PGG, A NOVEL IMMUNE MODULATOR, IN THE 1ST-LINE TREATMENT OF STAGE IV NSCLC: RESULTS FROM A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 2 STUDY by Engel-Riedel, W., Schneller, F., Wolf, M., Schuette, W., Lowe, J., Mattson, P., Gargano, M., Patchen, M.L., Huhn, R.D., Braun, A.

“…Abstract Aim: In a recent phase 2 trial of patients (pts) with stage IV NSCLC, Imprime PGG (PGG) in combination with carboplatin/paclitaxel chemotherapy (C/P)…”
Get full text

Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer (Nsclc) with Imprime Pgg (Ipgg) in Combination with Cetuximab, Carboplatin and Paclitaxel–Analysis of Secondary Endpoints of a Multicenter, Randomized Phase 2 Trial by Schneller, F., Thomas, M., Sadjadian, P., Kollmeier, J., Bose, N., Patchen, M.L., Lowe, J., Mattson, P., Gargano, M., Huhn, R.D., Braun, A.

Get full text